Orano - Annual Activity Report 2024 44 2 SITUATION AND ACTIVITIES OF THE COMPANY AND ITS SUBSIDIARIES DURING THE PAST FINANCIAL YEAR The group’s businesses Orano’s other activities include the other cross-business functions, as well as Nuclear Medicine. Nuclear Medicine Orano’s Nuclear Medicine business is mainly carried out by Orano Med, its medical subsidiary. Orano Med has developed a unique process to extract and produce lead-212 (212Pb), which is a particularly rare alpha-emitting radioactive isotope, at a very high degree of purity. Orano Med is developing promising treatments that combine lead-212 with various biological molecules that target cancer cells. This innovative approach is called targeted alpha-therapy. It can recognize and destroy cancer cells selectively, limiting the impact on surrounding healthy cells. Orano Med’s ambition is to develop effective and targeted anticancer therapies in two strategic areas: ● developing innovative treatments using Orano Med’s lead-212 through scientific partnerships or 100% Orano Med projects; and ● building the production plants to produce high-purity lead-212 and thus meet the needs of current clinical development and future marketing of drugs. ORANO MED’S ONCOLOGY R&D PIPELINE Discovery Indication (target) PoC Pre-IND Phase 1 Phase 2/3 Program Partners AlphaMedix TM Undisclosed Undisclosed Neuroendocrine tumors 212Pb-GRPR Solid tumors (breast and prostate cancer) 212Pb-PSMA 212Pb-PRIT Prostate cancer 212Pb DARPin Small-cell lung cancer 212Pb PRRT Undisclosed target 212Pb-PRRT Undisclosed target Undisclosed target Source: Orano 212Pb DARPinDLL3 / MP0712 Solid tumors 212Pb-PRRT Several targets 212Pb TAT Several targets Phage display platform Phage display platform 2.3.4 Other activities of Orano
RkJQdWJsaXNoZXIy NzMxNTcx